OTCMKTS:INVVY Indivior - INVVY Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. $25.65 +0.31 (+1.22%) (As of 02/6/2023 12:00 AM ET) Add Compare Share Share Today's Range$24.87▼$26.5050-Day Range$20.14▼$25.9052-Week Range$14.22▼$26.50Volume2,927 shsAverage Volume2,910 shsMarket Capitalization$3.50 billionP/E Ratio24.43Dividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsHeadlinesShort Interest About Indivior (OTCMKTS:INVVY) StockIndivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.Read More Receive INVVY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter. Email Address INVVY Stock News HeadlinesJanuary 12, 2023 | thestreet.comIndivior Shares Plunge Amid Generics Threat to Suboxone Opioid TreatmentNovember 14, 2022 | finance.yahoo.comIndivior To Pay Over 100% Premium To Buy Opioid Focused Player Opiant PharmaceuticalsFebruary 7, 2023 | Investing Trends (Ad)Profit From the Commercial Solar Boom?Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered. October 12, 2022 | uk.investing.comLondon midday: FTSE flat, sterling up as BoE confirms end of bond-buying programme By Sharecast - Investing.com UKOctober 4, 2022 | uk.finance.yahoo.comAelis Farma CEO Pier Vincenzo Piazza Receives the EY Entrepreneur of the Year Award - Yahoo Finance UKOctober 4, 2022 | businesswire.comAelis Farma CEO Pier Vincenzo Piazza Receives the EY Entrepreneur of the Year Award - Business WireSeptember 30, 2022 | benzinga.comIndivior Shareholders Approve Resolutions to Proceed with Additional U.S. Listing - Indivior (OTC:INVVY) - BenzingaSeptember 27, 2022 | finance.yahoo.comAelis Farma: Availability of the 2022 Half-year Financial Report - Yahoo FinanceFebruary 7, 2023 | Investing Trends (Ad)Profit From the Commercial Solar Boom?Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered. September 26, 2022 | streetinsider.comAelis Farma reports 2022 half-year financial results and confirms its development objectives - StreetInsider.comSeptember 22, 2022 | streetinsider.comAelis Farma Will Participate in the Addiction 2022 Conference Dedicated to Innovation in the Treatment of Addictions - StreetInsider.comSeptember 7, 2022 | finance.yahoo.comIndivior To Participate in Upcoming Investor Healthcare Events - Yahoo FinanceAugust 22, 2022 | streetinsider.comAdial Pharmaceuticals (ADIL) Appoints Cary Claiborne as CEO - StreetInsider.comAugust 18, 2022 | streetinsider.comAddex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update - StreetInsider.comAugust 17, 2022 | benzinga.comHypocrisy All Around: Pfizer, NFL Are Hidden Sponsors Of Anti-Drug Group Fighting Against Cannabis Legali - BenzingaAugust 15, 2022 | finance.yahoo.comAddex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders - Yahoo FinanceAugust 4, 2022 | nasdaq.comHere's Why Momentum in Indivior PLC (INVVY) Should Keep going - NasdaqAugust 4, 2022 | finance.yahoo.comHere's Why Momentum in Indivior PLC (INVVY) Should Keep goingJuly 28, 2022 | fool.co.ukAre these 3 cheap stocks to buy after the latest results? - Motley Fool UKJuly 28, 2022 | lse.co.ukIndivior profits fall on higher costs ahead of US listing | Financial News - London South EastJuly 28, 2022 | marketwatch.comIndivior 1H Pretax Profit Fell as Costs Rose - MarketWatchJuly 20, 2022 | globenewswire.comGlobal Naloxone Market to surpass US$ 2,460.2 Million by - GlobeNewswireJune 24, 2022 | marketwatch.comIndivior Settles Opioid Addiction Treatment Litigation With Dr. Reddy's - MarketWatchJune 19, 2022 | streetinsider.comAddex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson's Disease due to Slow Recruitment Rate - StreetInsider.comJune 2, 2022 | uk.finance.yahoo.comTwo factors to watch at Indivior - Yahoo Finance UKJune 1, 2022 | morningstar.co.ukTRADING UPDATES: Indivior, Diurnal start trials; Alien Metals tests - MorningstarMay 19, 2022 | finance.yahoo.comFor Mental Health Awareness Month, Indivior Offers Hope for Opioid Use Disorder Recovery Through One Man's Inspiring Story - Yahoo FinanceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive INVVY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter. Email Address INVVY Company Calendar Today2/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:INVVY Previous SymbolNASDAQ:INVVY CUSIPN/A CIKN/A Webwww.indivior.com Phone804-379-1090Fax804-379-1215Employees800Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$1.05 Trailing P/E Ratio24.43 Forward P/E Ratio22.30 P/E GrowthN/ANet Income$205 million Net Margins18.04% Pretax Margin21.15% Return on Equity66.83% Return on Assets7.91% Debt Debt-to-Equity Ratio1.03 Current Ratio1.70 Quick Ratio1.58 Sales & Book Value Annual Sales$791 million Price / Sales4.42 Cash Flow$1.17 per share Price / Cash Flow21.97 Book Value$1.45 per share Price / Book17.69Miscellaneous Outstanding Shares136,300,000Free FloatN/AMarket Cap$3.50 billion OptionableNot Optionable Beta0.28 Key ExecutivesMark CrossleyChief Executive Officer & Executive DirectorRyan PreblickChief Financial Officer & Executive DirectorChristian HeidbrederChief Scientific OfficerCynthia CetaniChief Compliance & Integrity OfficerNina DeLorenzoChief Global Impact OfficerKey CompetitorsHUTCHMEDNASDAQ:HCMPTC TherapeuticsNASDAQ:PTCTAxsome TherapeuticsNASDAQ:AXSMEvotecOTCMKTS:EVTCYUltragenyx PharmaceuticalNASDAQ:RAREView All Competitors INVVY Stock - Frequently Asked Questions Should I buy or sell Indivior stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INVVY shares. View INVVY analyst ratings or view top-rated stocks. How have INVVY shares performed in 2023? Indivior's stock was trading at $22.60 at the beginning of 2023. Since then, INVVY shares have increased by 13.5% and is now trading at $25.65. View the best growth stocks for 2023 here. Are investors shorting Indivior? Indivior saw a drop in short interest in December. As of December 30th, there was short interest totaling 9,800 shares, a drop of 14.8% from the December 15th total of 11,500 shares. Based on an average daily volume of 2,400 shares, the days-to-cover ratio is currently 4.1 days. View Indivior's Short Interest. What is Indivior's stock symbol? Indivior trades on the OTCMKTS under the ticker symbol "INVVY." How do I buy shares of Indivior? Shares of INVVY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Indivior's stock price today? One share of INVVY stock can currently be purchased for approximately $25.65. How much money does Indivior make? Indivior (OTCMKTS:INVVY) has a market capitalization of $3.50 billion and generates $791 million in revenue each year. The company earns $205 million in net income (profit) each year or $1.05 on an earnings per share basis. How many employees does Indivior have? The company employs 800 workers across the globe. How can I contact Indivior? Indivior's mailing address is 10710 Midlothian Turnpike, North Chesterfield VA, 23235. The official website for the company is www.indivior.com. The company can be reached via phone at 804-379-1090, via email at investorrelations@indivior.com, or via fax at 804-379-1215. This page (OTCMKTS:INVVY) was last updated on 2/7/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.